Hepatitis B Virus (HBV)

CAS No.	Product Name	Inquiry
1951476-79-1	Fosclevudine-alafenamide Fosclevudine alafenamide (Compound EIDD-02173) is an antiviral agent with an EC50 of 1.71 μM against HBV.
1967002-25-0	Hbv-IN-41
198821-22-6	Merimepodib Merimepodib is orally bioavailable IMPDH inhibitor.
19956-53-7	Lucidone Lucidone, coming from the root of Lindera strychnifolia, may possess antioxidant and anti-inflammatory properties and may be useful for the prevention of free radical-induced skin damage. The anti-inflammatory activity of lucidone might cause by the inhibition of iNOS and COX-2 expressions through the down-regulation of NF-κB and AP-1 binding activity. Besides, the effects of lucidone on tyrosinase and antimelanogenic activity were investigated, lucidone strongly inhibits the activity of mushroom tyrosinase. The antimelanogenic activity of lucidone is probably due to its inhibition of tyrosinase activity and the suppression of tyrosinase and MITF expression.
201341-05-1	Tenofovir Disoproxil Tenofovir dsoproxil is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
203935-39-1	Helioxanthin derivative 5-4-2 Helioxanthin derivative 5-4-2 had potent anti-HBV activities in HepG2.2.15 cells, with the EC50s of 1 and 0.08 microM, respectively. The lamivudine-resistant HBV, L526M/M550V double mutant strain, was also sensitive to helioxanthin and 5-4-2. This class of compounds not only inhibited HBV DNA, but also decreased HBV mRNA and HBV protein expression. The EC50 of HBV DNA inhibition was consistent with the EC50 of HBV 3.5 Kb transcript inhibition, which was 1 and 0.09 microM for helioxanthin and 5-4-2 respectively.
20547-45-9	Paederoside antiphlogosis
2055006-79-4	Lenvervimab
2072057-17-9	RG7834 RG7834 is a highly selective and orally bioavailable HBV inhibitor, suppressing HBV antigens (both HBsAg and HBeAg) and virion production.
2090064-66-5	Vebicorvir Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM.
210474-65-0	L-Fd4A
211362-85-5	Brain Derived Basic Fibroblast Growth Factor (1-24)
211364-06-6	AT-130 AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.
2133017-36-2	GLP-26 GLP-26 is an HBV capsid assembly modulator (CAM) that inhibits HBV DNA replication (IC50 = 3 nM) in Hep AD38 system and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts pregenomic RNA encapsulation, leading to nucleocapsid disintegration and reduced cccDNA pools.
2137847-19-7	Canocapavir Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B.
2161364-69-6	HBV-IN-25 HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA(cid:0)452 μg/mL) and good PK property with no cellular toxicity.
2170998-69-1	HBV-IN-9 HBV-IN-9, a potent HBsAg (HBV Surface antigen) inhibitor (IC50 = 10 nM), is an HBV DNA production inhibitor with an IC50 of 0.15 nM in HepG2.2.15 cells. (Extracted from patent WO2018001952A1, example 20)
2172788-92-8	Inarigivir ammonium Inarigivir ammonium, a dinucleotide antiviral drug, significantly reduces liver HBV DNA in transgenic mice expressing hepatitis B virus and acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses.
2173356-23-3	HBV-IN-39-d3
221662-50-6	L-2'-Fd4C

※ Please kindly note that our services are for research use only.